Pgp contributes to therapy resistance in acute myeloid leukemia [44,45,46], ovarian and breast cancer [47,48], ependymoma [49], medulloblastoma [50], melanoma [51], and hepatocellular carcinoma [52]. Here, PGP is linked to medulloblastoma.